Wall Street brokerages expect that Mustang Bio Inc (NASDAQ:MBIO) will post ($0.20) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Mustang Bio’s earnings. Mustang Bio posted earnings of ($0.27) per share during the same quarter last year, which indicates a positive year over year growth rate of 25.9%. The business is scheduled to report its next quarterly earnings report on Tuesday, November 13th.

According to Zacks, analysts expect that Mustang Bio will report full-year earnings of ($0.84) per share for the current fiscal year. For the next financial year, analysts expect that the firm will post earnings of ($0.90) per share. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Mustang Bio.

Mustang Bio (NASDAQ:MBIO) last released its earnings results on Monday, August 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.06.

MBIO has been the topic of several analyst reports. ValuEngine upgraded Mustang Bio from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Zacks Investment Research lowered Mustang Bio from a “buy” rating to a “hold” rating in a report on Tuesday, May 22nd.

MBIO traded up $0.15 on Wednesday, hitting $6.33. 1,311 shares of the company were exchanged, compared to its average volume of 90,719. Mustang Bio has a 12 month low of $5.87 and a 12 month high of $13.35. The firm has a market capitalization of $173.79 million and a PE ratio of -8.24.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MBIO. Wells Fargo & Company MN acquired a new position in Mustang Bio during the fourth quarter worth approximately $164,000. Geode Capital Management LLC acquired a new position in Mustang Bio during the fourth quarter worth approximately $639,000. Goldman Sachs Group Inc. acquired a new position in Mustang Bio during the fourth quarter worth approximately $131,000. Millennium Management LLC acquired a new position in Mustang Bio during the fourth quarter worth approximately $326,000. Finally, Northern Trust Corp increased its position in Mustang Bio by 76.7% during the first quarter. Northern Trust Corp now owns 28,364 shares of the company’s stock worth $310,000 after buying an additional 12,316 shares during the last quarter. Institutional investors and hedge funds own 4.78% of the company’s stock.

Mustang Bio Company Profile

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T (CAR T) cell technology. The company's CAR T product candidates include MB-101, a IL13Ra2 CAR T cell program which is in Phase I clinical study for glioblastoma; and MB-102, a CD123 CAR T cell program to treat acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; and MB-106, a CD20 CAR T cell program that is in Phase I clinical study for the treatment of B cell non-Hodgkin lymphoma.

Recommended Story: Average Daily Trade Volume – ADTV

Get a free copy of the Zacks research report on Mustang Bio (MBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mustang Bio (NASDAQ:MBIO)

Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.